Program
saroglitazar
Also written as “Saroglitazar Magnesium 1 mg”, “Saroglitazar Magnesium 2 mg” and “Saroglitazar Magnesium 4 mg”.
Its studies are mostly in Non-alcoholic Fatty Liver Disease · Liver Cirrhosis, Biliary · Fibrosis · Renal Insufficiency · Dyslipidemias, led by Zydus Lifesciences.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Zydus Lifesciences | 196 open or running | phase 4since May 13, 2023 | Feb 7, 2017 | Dec 31, 2026phase 1 · NCT05045482 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 5 studies since Feb 7, 2017.
- Feb 24, 2019Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT03863574 · 16 enrolled · United States
- Aug 1, 2019Phase 1 study in HealthyNCT04045769 · 52 enrolled · India
- Sep 11, 2019Phase 1 study in HealthyNCT04112446 · 8 enrolled · United States
- Jun 15, 2020Phase 1 study in Renal InsufficiencyNCT04446507 · 32 enrolled · United States
- Jul 9, 2020Phase 1 study in Hepatic ImpairmentNCT04469920 · 98 enrolled · United States
- Jul 11, 2021Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT05011305 · 189 enrolled · United States, Argentina, Puerto Rico and more
- Jul 25, 2021Phase 1 study in FibrosisNCT05045482 · 30 planned · United States
- Nov 1, 2021Phase 3 study in Liver Cirrhosis, BiliaryNCT05133336 · 196 enrolled · United States, Argentina, Iceland and more
- Jan 24, 2022Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT05211284 · 4 enrolled · United States
- May 13, 2023Phase 4 study in Non-alcoholic Fatty Liver DiseaseNCT05872269 · 1,500 planned · India
- May 9, 2024Phase 3 study in Liver Cirrhosis, BiliaryNCT06427395 · 102 enrolled · United States, Argentina, Turkey (Türkiye)
- Feb 9, 2025Phase 1 study in Liver Cirrhosis, BiliaryNCT06825559 · 6 planned · United States
- Oct 5, 2025Phase 3 study in Liver Cirrhosis, BiliaryNCT07216235 · 386 planned · United States
- Dec 26, 2025Phase 3 study in Liver Cirrhosis, BiliaryNCT07424677 · 90 planned · United States
Ahead
- Dec 31, 2026Primary completion: phase 1 study in Liver Cirrhosis, BiliaryNCT06825559
- Dec 31, 2026Primary completion: phase 1 study in FibrosisNCT05045482
- Apr 18, 2027Primary completion: phase 3 study in Liver Cirrhosis, BiliaryNCT06427395
- Jul 2028Primary completion: phase 3 study in Liver Cirrhosis, BiliaryNCT07424677
TargetBeta
“Peroxisome proliferator-activated receptor alpha agonist; Peroxisome proliferator-activated receptor gamma agonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| chiglitazarrule | Chipscreen Biosciences | phase 3 | 9 |
| lanifibranor | inventiva-pharma | phase 3 | 6 |
Studies
All 19 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07424677Liver Cirrhosis, Biliary · United States | 3 | Recruiting | Jul 2028 | 90 |
| NCT07216235Liver Cirrhosis, Biliary · United States | 3 | Recruiting | Nov 2032 | 386 |
| NCT06825559Liver Cirrhosis, Biliary · United States | 1 | Recruiting | Dec 31, 2026 | 6 |
| NCT06427395Liver Cirrhosis, Biliary · United States, Argentina, Turkey (Türkiye) | 3 | Active, not recruiting | Apr 18, 2027 | 102 |
| NCT05872269Non-alcoholic Fatty Liver Disease · India | 4 | Recruiting | Jan 10, 2025 | 1,500 |
| NCT05211284Non-alcoholic Fatty Liver Disease · United States | 2 | Terminated | Oct 2, 2023 | 4 |
| NCT05133336Liver Cirrhosis, Biliary · United States, Argentina, Iceland and more | 3 | Completed | Apr 30, 2025 | 196 |
| NCT05045482Fibrosis · United States | 1 | Recruiting | Dec 31, 2026 | 30 |
| NCT05011305Non-alcoholic Fatty Liver Disease · United States, Argentina, Puerto Rico and more | 2 | Completed | Sep 12, 2025 | 189 |
| NCT04469920Hepatic Impairment · United States | 1 | Completed | Mar 21, 2022 | 98 |
| NCT04446507Renal Insufficiency · United States | 1 | Completed | May 28, 2024 | 32 |
| NCT04112446Healthy · United States | 1 | Completed | Oct 29, 2019 | 8 |
| NCT04045769Healthy · India | 1 | Completed | Nov 27, 2019 | 52 |
| NCT03863574Non-alcoholic Fatty Liver Disease · United States | 2 | Completed | Mar 20, 2020 | 16 |
| NCT03639623Non-alcoholic Fatty Liver Disease · United States | 2 | Completed | Dec 13, 2021 | 20 |
| NCT03617263Non-alcoholic Fatty Liver Disease · United States, Mexico | 2 | Terminated | Oct 28, 2024 | 60 |
| NCT03112681Liver Cirrhosis, Biliary · United States | 2 | Completed | Aug 7, 2020 | 37 |
| NCT03097107Dyslipidemias · United States | 2 | Suspended | Dec 2023 | 124 |
| NCT03061721Non-alcoholic Fatty Liver Disease · United States | 2 | Completed | Aug 22, 2019 | 106 |
How it is read
Names in the registry
- “Saroglitazar Magnesium 1 mg”, 6 entries
- “Saroglitazar Magnesium 2 mg”, 5 entries
- “Saroglitazar Magnesium 4 mg”, 4 entries
- “Saroglitazar magnesium 1 mg”, 2 entries
- “Saroglitazar”, 2 entries
Conditions, from the studies’ own filings
- Non-alcoholic Fatty Liver Disease, 7 studies
- Liver Cirrhosis, Biliary, 6 studies
- Fibrosis, 1 study
- Renal Insufficiency, 1 study
- Dyslipidemias, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.